ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Conditions
Brief summary
To assess efficacy and safety of oral TQ-B3101 administered to patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that confirmed ROS1 positive gene mutation.
Interventions
DRUGTQ-B3101
TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1.18 years and older. 2.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1；Life expectancy ≥ 3 months. 3.Understood and Signed an informed consent form. 4.Histologically or cytologically confirmed locally advanced or metastatic NSCLC . 5.Subjects in the screening period should provide a written report of ROS1 positive, or tumor histological specimens obtained at the time of diagnosis/post before enrollment are sent to the central laboratory to confirm ROS1 positive. 6\. Had received no more than two chemotherapy regimens. 7.At least 1 measurable tumor lesion other than brain lesions within 28 days before first dose based on RECIST 1.1. 8.The main organs function are normally, the following criteria are met: 1. routine blood tests（no blood transfusion and blood products within 14 days）：hemoglobin（Hb）≥90g/L；absolute neutrophil count（ANC）≥1.5×109/L； platelets（PLT）≥100×109/L. 2. Blood biochemical examination: alanine transaminase（ALT）and aspartate aminotransferase（AST）≤2.5×upper limit of normal (ULN)（when the liver is invaded, ALT, and AST ≤5× upper limit of normal (ULN) ）； total bilirubin (TBIL)≤1.5×upper limit of normal (ULN)；Serum creatinine ≤ 1.5 × upper limit of normal (ULN); or creatinine clearance calculated ≥ 50ml / min (calculated according to Cockcroft-Gault formula); 3. left ventricular ejection fraction (LVEF) measured by the Cardiac echocardiography ≥ 50%. 9.Women must meet one of the following conditions:has undergone surgical sterilization;have been menopausal at least 1 year;have fertility, the following conditions must be met;Serum pregnancy test results were negative; throughout the study period to 6 months after the last dose, agreed to adopt an approved method of contraception (for example: oral contraception, injection contraception or implanted, barrier-effect Contraceptive methods, spermicides and condoms, or intrauterine devices).Men must meet one of the following conditions:has surgical sterilization;an approved method of contraception must be used throughout the study period and 6 months after the last dose.
Exclusion criteria
1. Has any known endothelial growth factor receptor (EGFR) positive mutation. 2. Prior therapy with crizotinib, anti-programmed cell death (PD)-1, anti-PD-L1 or any other ROS1 inhibitor. 3. Has multiple factors affecting oral medication, such as inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc. 4. Has diagnosed and/or treated additional malignancy within 5 years prior to randomization with the exception of cured carcinoma in situ of the cervix、 non-melanoma skin cancers and superficial bladder tumors. 5. Has a history of hypertensive crisis, hypertensive encephalopathy; or uncontrolled hypertension. 6. Has clinically significant, uncontrolled cardio-cerebral vascular disease. 7. Has major surgery and anti-tumor treatment before two weeks of treatment and participated in other drug clinical trials within four weeks. 8. Has known central nervous system metastasis and/or spinal cord compression, cancerous meningitis, and pia mater disease. 9. Has in screening period confirmed HCV positive, HIV positive, active syphilis positive, or HBsAg positive, HBV DNA titers \>500 copies/ml and stable time \<14 days after symptomatic treatment,or has a history of stem cells and organ transplantation. 10. Has history of psychotropic substance abuse that unable to abstain from or mental disorder. 11. According to the judgement of the researchers, there are other factors that may lead to the termination of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) | up to approximately 20 months | Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DOR) | up to approximately 20 months | DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. |
| Disease control rate (DCR) | up to approximately 20 months | Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD). |
| Progression-free survival (PFS) | up to approximately 20 months | PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause. |
| Overall survival (OS) | up to approximately 24 months | OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. |
Countries
China
Contacts
Primary ContactShun Lu, Doctor
Outcome results
None listed